文献速递类风湿关节炎

改善病情抗风湿药对类风湿关节炎最相关患者报告结局领域影响的Meta分析

Meta-Analyses on the Effects of Disease-Modifying Antirheumatic Drugs on the Most Relevant Patient-Reported Outcome Domains in Rheumatoid Arthritis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2023-02-22

该系统综述纳入52项随机对照试验的69条记录,评估改善病情抗风湿药(DMARDs)对疼痛、疲劳、活动受限、整体情绪与身体健康影响及工作/上学/家务能力和效率5个患者相关领域的影响。Meta分析显示,与安慰剂和甲氨蝶呤相比,DMARDs在疼痛、疲劳和活动受限领域均降低负担,效应量可能受DMARD类型影响。

要点

  • 与安慰剂相比,DMARDs在疼痛、疲劳和活动受限领域的标准化均数差分别为-0.80、-0.48和-0.56。
  • 与甲氨蝶呤相比,DMARDs在上述三领域的标准化均数差分别为-0.55、-0.44和-0.37。
  • 作者认为,在类风湿关节炎治疗决策中应考虑患者报告结局。

核心结论

  • DMARDs降低所有患者相关领域的负担,效应量可能受DMARD类型影响。
  • 作者认为,在类风湿关节炎治疗决策中应考虑患者报告结局。

研究设计与样本

  • 系统综述与随机效应Meta分析,检索随机对照试验,比较已注册DMARDs与安慰剂或甲氨蝶呤对国际健康结局测量联盟(ICHOM)炎症性关节炎标准集中患者报告结局的影响。
  • 共纳入52项研究的69条记录,覆盖5个患者相关领域。
  • 对疼痛、疲劳和活动受限3个领域,以变化分数的标准化均数差为效应量进行随机效应Meta分析;其余2个领域采用叙述性呈现。

主要发现

  • 与安慰剂相比,DMARDs在疼痛领域的标准化均数差为-0.80(95%CI -0.99至-0.61)。
  • 与安慰剂相比,DMARDs在疲劳领域的标准化均数差为-0.48(95%CI -0.64至-0.32)。
  • 与安慰剂相比,DMARDs在活动受限领域的标准化均数差为-0.56(95%CI -0.63至-0.49)。
  • 与甲氨蝶呤相比,DMARDs在疼痛、疲劳和活动受限领域的标准化均数差分别为-0.55(95%CI -0.70至-0.41)、-0.44(95%CI -0.55至-0.33)和-0.37(95%CI -0.44至-0.30)。

关键数值与推荐

  • 与安慰剂相比,DMARDs在疼痛领域标准化均数差-0.80(95%CI -0.99至-0.61)。
  • 与安慰剂相比,DMARDs在疲劳领域标准化均数差-0.48(95%CI -0.64至-0.32)。
  • 与安慰剂相比,DMARDs在活动受限领域标准化均数差-0.56(95%CI -0.63至-0.49)。
  • 与甲氨蝶呤相比,DMARDs在疼痛领域标准化均数差-0.55(95%CI -0.70至-0.41),在疲劳领域-0.44(95%CI -0.55至-0.33),在活动受限领域-0.37(95%CI -0.44至-0.30)。

临床怎么用

  • 作者认为,在类风湿关节炎治疗决策中应考虑患者报告结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Whereas in the treatment of rheumatoid arthritis much evidence exists on the effects of current pharmacologic treatment on clinical outcomes, little is known about the effects on patient-reported outcomes. This systematic review aims to evaluate the effects of disease-modifying antirheumatic drugs (DMARDs) on the patient-relevant domains of pain, fatigue, activity limitation, overall emotional and physical health impact, and work/school/housework ability and productivity. METHODS: A literature search was conducted to identify randomized controlled trials wherein registered DMARDs were compared with placebo or methotrexate and reported the effects on patient-reported outcomes included in the International Consortium of Health Outcomes Measurement standard set for inflammatory arthritis. Random effects meta-analyses using the standardized mean differences of change scores as the effect measure were performed for the domains of pain, fatigue, and activity limitation, comparing DMARDs with placebo and methotrexate. The other 2 domains were presented narratively. RESULTS: Across the 5 domains, 69 records belonging to 52 studies were identified. All meta-analyses showed a decrease of burden when DMARDs were compared with placebo (standardized mean differences [95% confidence interval] in pain -0.80 [-0.99, -0.61], fatigue -0.48 [-0.64, -0.32], and activity limitation -0.56 [- 0.63, -0.49]) and when compared with methotrexate (-0.55 [-0.70, -0.41), -0.44 [-0.55, -0.33], and - 0.37 [-0.44, -0.30], respectively). CONCLUSION: DMARDs decrease the burden in all the domains that are relevant to patients. Effect sizes may be influenced by DMARD type. Therefore, in the decision for rheumatoid arthritis treatment, patient-reported outcomes should be taken into account.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. van den Dikkenberg M, Luurssen-Masurel N, Kuijper TM, et al. Meta-Analyses on the Effects of Disease-Modifying Antirheumatic Drugs on the Most Relevant Patient-Reported Outcome Domains in Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2023. PMID: 35657611. doi:10.1002/acr.24965

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。